相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Propensity Score Adjustment With Multilevel Data: Setting Your Sites on Decreasing Selection Bias
Michael E. Griswold et al.
ANNALS OF INTERNAL MEDICINE (2010)
Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis
Chamila Geeganage et al.
BMC MEDICINE (2010)
Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers
Kathleen Butler et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite
Miho Kazui et al.
DRUG METABOLISM AND DISPOSITION (2010)
Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects
Renli Teng et al.
DRUG METABOLISM AND DISPOSITION (2010)
Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects
Renli Teng et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Nonresponders to clopidogrel: pharmacokinetics and interactions involved
Mariano A. Giorgi et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans
Nagy A. Farid et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate
Laurent Bonello et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA Boxed Warning A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association
David R. Holmes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents
Neena S. Abraham et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
David N. Juurlink et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease The ONSET/OFFSET Study
Paul A. Gurbel et al.
CIRCULATION (2009)
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes
Jessica L. Mega et al.
CIRCULATION (2009)
Baseline Risk of Major Bleeding in Non-ST-Segment-Elevation Myocardial Infarction The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score
Sumeet Subherwal et al.
CIRCULATION (2009)
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
Alan R. Shuldiner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Frederick G. Kushner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Pharmacogenetics in Cardiovascular Antithrombotic Therapy
Francisco Marin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Risk of combining PPIs with thienopyridines: fact or fiction?
Dirk Sibbing et al.
LANCET (2009)
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
Michelle L. O'Donoghue et al.
LANCET (2009)
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
Jean-Philippe Collet et al.
LANCET (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events.
Tabassome Simon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: A look at the clinical and pharmacological evidence
Marie Lordkipanidze et al.
PHARMACOLOGY & THERAPEUTICS (2009)
Pharmacology of emerging novel platelet inhibitors
Dominick J. Angiolillo et al.
AMERICAN HEART JOURNAL (2008)
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
David S. Small et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
David S. Small et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Impact of Clopidogrel in Patients With Acute Coronary Syndromes Requiring Coronary Artery Bypass Surgery A Multicenter Analysis
Jeffrey S. Berger et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin
Martine Gilard et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects
Nagy A. Farid et al.
PHARMACOTHERAPY (2008)
Prasugrel achieves greater and faster P2Y(12) receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
Lars Wallentin et al.
EUROPEAN HEART JOURNAL (2008)
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention - The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial
Stephen D. Wiviott et al.
CIRCULATION (2007)
Cytochrome P4502C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients
Betti Giusti et al.
PHARMACOGENETICS AND GENOMICS (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
From ATP to AZD6140:: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis
Brian Springthorpe et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis
Piergiovanni Buonamici et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
N. A. Farid et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Variability in individual responsiveness to clopidogrel - Clinical implications, management, and future perspectives
Dominick J. Angiolillo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial
Gregg W. Stone et al.
LANCET (2007)
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
John T. Brandt et al.
AMERICAN HEART JOURNAL (2007)
Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol
Man Tang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Impact of P-glycoprotein on clopidogrel absorption
Dirk Taubert et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Jean-Sebastien Hulot et al.
BLOOD (2006)
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes - The ALBION (assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial
Gilles Montalescot et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:: a double-blind comparison to clopidogrel with aspirin
S Husted et al.
EUROPEAN HEART JOURNAL (2006)
Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450
JLF Rehmel et al.
DRUG METABOLISM AND DISPOSITION (2006)
Drug therapy - Drug metabolism and variability among patients in drug response
GR Wilkinson
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation - A new drug-drug interaction
WC Lau et al.
CIRCULATION (2003)
Structure and stereochemistry of the active metabolite of clopidogrel
JM Pereillo et al.
DRUG METABOLISM AND DISPOSITION (2002)
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
SR Mehta et al.
LANCET (2001)
分享论文
